Hims & Hers Health, Inc.

Freedom Broker now recommends clients buy shares of Hims &amp; Hers Health, a telehealth company, in the wake of a recent dip. The mid-cap stock has lost 35% of its market value due to a canceled partnership with pharma giant Novo Nordisk, which alleges that Hims&nbsp;&amp; Hers put patient safety at risk through “deceptive” marketing and sold a knockoff version of its drug Wegovy. Despite this, Freedom Broker analysts think Hims &amp; Hers stock will bounce back quickly.&nbsp;

Freedom Broker says buy Hims & Hers after cancellation of tie-up with Novo Nordisk

Novo Nordisk A/S

Eli Lilly and Company

Innovent Biologics is the first company in China to mount a real challenge to pharmaceutical giants Novo Nordisk and Eli Lilly in the obesity market. The approval of its weight loss drug opens a new chapter in the rapidly growing Chinese market, where local manufacturers are seeking to squeeze out foreign leaders with their expensive GLP-1 injections. What will the increased competition lead to and should the makers of Ozempic and Mounjaro be wary of the Chinese threat?

China approves Ozempic's first domestic competitor. What do investors need to know?

AstraZeneca PLC

At least a dozen companies are looking for a way to reduce muscle mass loss when taking weight loss drugs

Eli Lilly is entering a market valued at $30 billion, can it beat the competition?

Novo Nordisk's market value has fallen by nearly $400 billion in the ten months of the recession

Novo Nordisk shares recovered after the collapse. What will happen to the company next?

Shares of startup Verve soared more than 75% after the acquisition announcement


Eli Lilly will buy a genetic engineering startup. What signal does this send to investors?

Investors are hopeful that the company will be able to recover sales after the leadership change

Novo Nordisk regained its status as Europe's most valuable company on a day of falling markets

Danish drugmaker Novo Nordisk seeks new chief executive after share price slump

An activist investor has taken an interest in the manufacturer Ozempic. What is it known for?  

Alphabet Inc.

BioNTech SE

Tesla, Inc.

Daily review and forecast of events on the US stock market from&nbsp;Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

New York morning: focus on job stats, trade talks and new duties

LifeMD, Inc.

Quotes on the telehealth company LifeMD <a href="https://finance.yahoo.com/quote/LFMD/">jumped</a> more than 40% yesterday, April 29, after it announced that its platform would <a href="https://ir.lifemd.com/press-release-details.php?newsId=3070180">offer</a> one of the bestselling weight-loss drugs with no insurance approval required.

Telehealth company LifeMD to sell Ozempic alternative; shares soar 40%


MIRA Pharmaceuticals, Inc.

Quotes on MIRA Pharmaceuticals, a developer of treatments for neurological and neuropsychiatric disorders, <a href="https://finance.yahoo.com/quote/MIRA/">jumped</a> almost 20% yesterday, April 16, before giving back some of the gains in after-hours trading. The surge came after the company reported positive animal trial results of its drug candidate for diabetic neuropathy, a condition in which nerves are damaged due to high blood sugar levels.

MIRA Pharmaceuticals jumps 20% on successful trial of ketamine analog


Lisata Therapeutics, Inc.

Quotes on Lisata Therapeutics, a pharmaceutical company developing therapies to combat tumors, <a href="https://finance.yahoo.com/quote/LSTA/">gained</a> more than 10% yesterday, April 15, after it announced a partnership with one of the largest industry manufacturers, Catalent, to evaluate the efficacy of a promising Lisata therapy. Since December, Catalent has been owned by Novo Holdings, the controlling shareholder of Denmark’s Novo Nordisk, a global leader in weight-loss medications.

Biotech small cap Lisata Therapeutics jumps 10% on partnership with Novo subsidiary


Longeveron Inc.

Zacks Small-Cap Research (Zacks SCR) <a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_03202025_LGVN_Sorensen.pdf">believes</a> that Longeveron, a micro-cap developer of cellular therapies for aging-related diseases, is worth more than five times its current share price. Its outlook has been bolstered after U.S. authorities gave the <a href="https://scr.zacks.com/news/news-details/2025/LGVN-Announces-Positive-Alzheimers-News/default.aspx">green light</a> to trials of the company’s Alzheimer’s drug and granted it a special designation. Overall, Alzheimer’s drugs are <a href="https://www.bloomberg.com/news/articles/2025-01-10/alzheimer-s-drugs-from-lilly-novo-and-roche-in-focus-for-investors?sref=Y0jVLcFo&amp;utm_source=in_materials#:~:text=Investors%20seeking%20the%20next%20obesity%2Dlike%20market%20opportunity%20will%20be%20closely%20watching%20developments%20related%20to%20treatments%20for%20Alzheimer%E2%80%99s%20disease%20in%202025.">seen</a> as a highly promising niche for investors.

Pharmaceutical Companies